AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
DiscussionOur data demonstrated that MLN8237 improved the effect of immunology-related therapy on tumor cells by interacting with anti-PD-L1 antibody, which contributed to producing creative sparks for exploring the possible solutions to overcoming drug resistance to tumor targeted therapy.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Colorectal Cancer | Immunotherapy | Study